| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-06-28 | Nordic Nanovector (Norway) AREVA Med (France) | lead-212 conjugated anti-CD37 antibody | leukemias | R&D collaboration |
Cancer - Oncology | R&D agreement |
| 2016-06-28 | Novartis (Switzerland) Xencor (USA - CA) | bispecific antibodies | acute myeloid leukemia, B-cell malignancies | licensing - collaboration | Cancer - Oncology | Licensing agreement |
| 2016-06-27 | Pfizer (USA - NY) GE Healthcare (USA - WI) | production plant | construction of a production plant |
Construction of a production plant | ||
| 2016-06-26 | Oramed Pharmaceuticals (Israel) | nomination | Metabolic diseases | Nomination | ||
| 2016-06-24 | Takeda Pharmaceutical (Japan) Amgen (USA - CA) | AMG403 and AMG386 (trebananib) | development licensing |
Cancer - Oncology | Termination of the agreement | |
| 2016-06-24 | Paion (Germany) Cosmo Pharmaceuticals (Ireland) | remimazolam | licensing | CNS diseases | Licensing agreement | |
| 2016-06-23 | Alligator Bioscience (Sweden) Cobra Biologics (UK) | ADC-1013 | cancer | production - manufacturing | Cancer - Oncology | Production agreement |
| 2016-06-23 | Momenta Pharmaceuticals (USA - MA) | nomination |
Nomination | |||
| 2016-06-23 | Vaximm (Germany) | nomination | Cancer - Oncology | Nomination | ||
| 2016-06-22 | Affilogic (France) Sanofi (France) | Nanofitin®-conjugated biotherapeutics | R&D licensing |
Licensing agreement | ||
| 2016-06-21 | Txcell (France) Yeda Research and Development Company (Israel) Weizmann Institute of Science (Israel) | CAR-Treg patent for suppression of autoimmune and inflammatory diseases | option agreement licensing agreement |
Autoimmune diseases - Inflammatory diseases | Exercise of an option agreement | |
| 2016-06-21 | Adaptimmune Therapeutics (UK) Thermo Fisher Scientific (USA - MA) | Dynabeads™ CD3/CD28 Cell Therapy System | development distribution |
Technology - Services | Distribution agreement | |
| 2016-06-21 | Novadip Biosciences (Belgium) | opening of new premises |
Regenerative Medicine | Opening of new premises | ||
| 2016-06-21 | MDxHealth (Belgium) Duke University Health System (USA - NC) | ConfirmMDx® for Prostate Cancer test | prostate cancer | collaboration |
Cancer - Oncology - Diagnostic | Collaboration agreement |
| 2016-06-21 | Keryx Biopharmaceuticals (USA - NY) | nomination |
Nomination | |||
| 2016-06-21 | Kiadis Pharma (The Netherlands) PCT, a Caladrius Company (USA - CA) | ATIR101™ | hematological cancers | production manufacturing |
Technology - Services - Cancer - Oncology | Production agreement |
| 2016-06-21 | Xbrane Biopharma (Sweden) | biosimilar laboratory | opening of new premises |
Opening of new premises | ||
| 2016-06-20 | Cellectis (France) Servier (France) Pfizer (USA - NY) | UCART19 and five other product candidates targeting solid tumors | chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) | development |
Cancer - Oncology | Milestone |
| 2016-06-20 | Kite Pharma (USA - CA) | manufacturing facilities | opening of new premises |
Opening of new premises | ||
| 2016-06-20 | Gyros Protein Technologies (Sweden) | nomination |
Technology - Services | Nomination |
